Advertisement

Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

  • Ou Yamaguchi
  • Kyoichi KairaEmail author
  • Atsuto Mouri
  • Ayako Shiono
  • Kosuke Hashimoto
  • Yu Miura
  • Fuyumi Nishihara
  • Yoshitake Murayama
  • Kunihiko Kobayashi
  • Hiroshi Kagamu
Correction
  • 150 Downloads

Correction to: Cancer Chemotherapy and Pharmacology (2019) 83:817–825  https://doi.org/10.1007/s00280-019-03790-w

In the original publication of the article, the authors found few errors and the corrections are given below:
  1. 1.

    Abstract

     
Results: “By multivariate analysis, smoking, performance status (PS), and time on treatment of 1st TKI with more than 10 months were confirmed to be independent prognostic factors predicting a worse progression-free survival” has been changed to “By multivariate analysis, smoking, performance status (PS) and time on treatment of 1st TKI with more than 10 months were confirmed to be independent prognostic factors predicting a better progression-free survival (PFS)”.
  1. 2.

    Results

     

Patient demographics

EGFR mutation analysis revealed 35 patients with deletion of exon19, 19 patients with L858R (exon 21), and 2 patients with other mutations” has been changed to “EGFR mutation analysis revealed 35 patients with deletion of exon 19, 19 patients with L858R (exon 21), and 8 patients with other mutations”.
  1. 3.
    In the online publication of the article, the values in the Table 2 mentioned under the column smoking (N = 62) and also value under the Gender, the column under the PFS (HR), has incorrectly published. The corrected Table 2 has been given below:
    Table 2

    Univariate survival analysis according to different variables

    Variables

    N = 62

    PFS

    OS

    Median (days)

    HR

    95% CI

    p value

    Median (days)

    HR

    95% CI

    p value

    Age

     ≤ 69/> 69 years

    35/27

    174/194

    1.12

    0.64–1.92

    0.15

    572/485

    1.42

    0.76–2.65

    0.26

    Gender

        

     Male/female

    25/37

    144/209

    1.36

    0.91–3.03

    0.09

    532/587

    0.96

    0.51–1.81

    0.92

    Smoking

        

     Yes/no

    28/34

    213/94

    0.44

    0.24–0.82

    < 0.01

    572/551

    0.91

    0.49–1.68

    0.75

    ECOG PS

        

     0–1/2–3

    42/20

    227/73

    0.43

    0.23–0.83

    0.01

    778/153

    0.32

    0.15–0.67

    < 0.01

    BSA

       

     ≤ 1.5/> 1.5

    43/19

    168/227

    0.77

    0.43–1.39

    0.39

    501/904

    0.74

    0.38–1.45

    0.39

    EGFR mutation status

        

     Del 19/L858R

    35/19

    174/168

    0.99

    0.54–1.81

    0.98

    754/505

    0.59

    0.28–1.24

    0.12

    Time on treatment of prior EGFR-TKI (months)

        

     ≤ 6/> 6

    7/55

    60/195

    0.19

    0.05–0.66

    < 0.01

    145/587

    0.21

    0.05–0.78

    0.02

     ≤ 8/> 8

    11/51

    94/195

    0.33

    0.13–0.84

    0.02

    389/587

    0.32

    0.11–0.98

    0.04

     ≤ 10/> 10

    16/46

    73/222

    0.41

    0.19–0.87

    0.02

    389/587

    0.36

    0.14–0.87

    0.02

     ≤ 12/> 12

    17/45

    85/209

    0.43

    0.21–0.91

    0.02

    389/587

    0.42

    0.18–0.96

    0.04

     ≤ 14/> 14

    22/40

    73/238

    0.36

    0.18–0.71

    < 0.01

    389/667

    0.34

    0.16–0.72

    < 0.01

     ≤ 20/> 20

    32/30

    109/256

    0.45

    0.25–0.81

    < 0.01

    532/754

    0.63

    0.34–1.17

    0.14

    Time from prior EGFR-TKI to afatinib (months)

        

     ≤ 4/> 4 

    39/23

    168/209

    0.63

    0.36–1.11

    0.11

    505/704

    0.68

    0.36–1.26

    0.22

     ≤ 6/> 6

    42/20

    194/191

    0.71

    0.40–1.24

    0.22

    532/704

    0.78

    0.41–1.46

    0.44

     ≤ 12/> 12

    52/10

    194/134

    0.60

    0.29–1.21

    0.15

    551/704

    0.82

    0.37–1.76

    0.61

    Cytotoxic agent between prior EGFR-TKI and afatinib

       

     Yes/no

    31/31

    194/164

    0.73

    0.42–1.27

    0.26

    532/704

    0.53

    0.28–1.00

    0.05

    Initial dosage of afatinib

       

     40/20 or 30 mg

    46/16

    171/238

    1.22

    0.67–2.21

    0.52

    551/667

    1.21

    0.59–2.43

    0.61

    Disease stage at the initiation of prior EGFR-TKI

        

     IV/recurrence after surgical resection

    43/19

    174/194

    1.46

    0.83–2.03

    0.19

    551/587

    1.42

    0.76–2.67

    0.29

    Treatment line of afatinib

        

     ≤ 3/> 3 lines

    33/29

    213/168

    0.66

    0.38–1.13

    0.11

    572/551

    1.02

    0.55–1.86

    0.95

    Numbers of initial EGFR-TKI before afatinib

        

     ½

    36/26

    209/156

    0.59

    0.34–1.03

    0.05

    667/437

    0.59

    0.32–1.09

    0.08

    Bold indicates statistically significant difference

    ECOG eastern cooperative oncology group, PS performance status, PFS progression free survival, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, BSA body surface area

     
  2. 4.

    Under the figure 1, the text in the figure legends has been incorrectly published. The corrected text is given below:

     
“A statistically significant difference in the PFS (p = 0.22) (C) and OS (p = 0.44) (D) was not observed in the patients between more than and less than 6 months”.
  1. 5.
    The captions for the Figure 2 has been changed from
    1. a)

      TTF of prior EGFR-TKI: > 10 months ≤ 10 months to Time on treatment of prior EGFR-TKI: > 10 months ≤10 months

       
    2. b)

      TTF of prior EGFR-TKI: > 10 months ≤10 months to Time on treatment of prior EGFR-TKI: > 10 months ≤10 months.

       
     
The corrected Fig.  2 has been given below:
Fig. 2

Series 62 Model 4666 extrapolations

  1. 6.

    In the online published article, the Figure legends under the figure 2 has been changed from

     

“Forest plot of 5-year PFS (a) and OS (b) rates according to time on treatment using cut-off values of 10 months in each variables” to

“Forest plot of PFS (a) and OS (b) rates according to time on treatment using cut-off values of 10 months in each variables”.

Notes

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ou Yamaguchi
    • 1
  • Kyoichi Kaira
    • 1
    Email author
  • Atsuto Mouri
    • 1
  • Ayako Shiono
    • 1
  • Kosuke Hashimoto
    • 1
  • Yu Miura
    • 1
  • Fuyumi Nishihara
    • 1
  • Yoshitake Murayama
    • 1
  • Kunihiko Kobayashi
    • 1
  • Hiroshi Kagamu
    • 1
  1. 1.Department of Respiratory Medicine Comprehensive Cancer Center, International Medical CenterSaitama Medical UniversityHidaka-CityJapan

Personalised recommendations